27 citations
,
October 2020 in “Drugs” This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
4 citations
,
July 2022 in “Clinical Cosmetic and Investigational Dermatology” This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
3 citations
,
March 2019 in “Journal of Pigmentary Disorders” This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.
June 2026 in “International Journal of Innovative Technologies in Social Science” This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” This review discusses the multifactorial pathogenesis of acne and current treatment strategies including the use of isotretinoin and spironolactone, but reports no new clinical results.
This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.
11 citations
,
July 2017 in “Expert Opinion on Investigational Drugs” This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
7 citations
,
December 2019 in “American Journal of Clinical Dermatology” This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.
1 citations
,
November 2018 in “Therapeutic Delivery” This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
13 citations
,
November 2013 in “Seizure: European Journal of Epilepsy” This study reports that hair loss may be a rare side effect of levetiracetam in epilepsy patients and appears reversible upon dose reduction or cessation.
March 2025 in “Canadian dermatology today.” In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.
37 citations
,
April 2011 in “Journal of Biological Chemistry” This study discovered a novel interaction between the vitamin D receptor and LEF1, essential for normal Wnt signaling in keratinocytes, which is crucial for regular hair cycling.
68 citations
,
May 2024 in “International Journal of Molecular Sciences” This review of acne management strategies highlights current treatments, such as topical and systemic therapies, procedural methods, and dietary changes, while also discussing emerging options like biologics and probiotics as potential future treatments, emphasizing personalized care due to acne's complex nature.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
April 2025 in “International Journal of Molecular Sciences” This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
April 2025 in “Current Pediatrics Reports” Transgender and gender-diverse teens need specialized skin and mental health care.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.
January 2025 in “Dermatology and Therapy” This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.
5 citations
,
August 2013 in “Epilepsy & Behavior”
November 2022 in “Piretc” This review discusses the historical development and market presence of financial leasing, emphasizing its advantages, but reports no new research findings.
1 citations
,
March 2004 in “Military Medicine” This case report describes a 57-year-old male who developed bilateral ankle swelling and pain, potentially linked to a recent episode of fever and chills following prostatitis treatment.
December 2025 in “International Journal of Surgery” In this study, researchers identified a causal link between Epstein-Barr virus infection and clear cell renal cell carcinoma, highlighting GBP1 as a key target and suggesting finasteride as a potential inhibitor, offering a new direction for treatment strategies.
5 citations
,
January 2009 in “Law and Contemporary Problems” This review discusses the role of lenders in the parenthood market and financing options for assisted reproduction and adoption, presenting various legal and economic implications without reporting new research results.
10 citations
,
January 2010 in “Journal of cosmetic and laser therapy” This article describes a non-blinded study investigating low level laser therapy for seven patients but reports no new clinical findings.
August 2025 in “Tropical Journal of Natural Product Research” In this study, LEON gel—an innovative nanoliposome-based delivery system for lavender essential oil—showed significant hair growth acceleration in male white rats without causing irritation, suggesting enhanced effectiveness compared to traditional essential oil use.
4 citations
,
March 2002 in “International journal of toxicology” In this study on tolerant rats, maternal and developmental toxicity from levo-alpha-acetyhnethadol hydrochloride were observed at all doses, without specific fetal toxicity or teratogenic effects.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This case study reports that a 30-year-old woman with persistent hair fall experienced marked improvement following leech therapy (Jalaukavacharana) performed according to classical Ayurvedic protocols.